Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1

Status

Withdrawn 1Terminated 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 4OTHER 2NETWORK 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 4

Conditions

Breast Neoplasms 41Carcinoma, Non-Small-Cell Lung 28Lung Neoplasms 8Triple Negative Breast Neoplasms 6Neoplasm Metastasis 6Neoplasms 5Uterine Cervical Neoplasms 4Recurrence 2Mesothelioma 2Lymphoma, Non-Hodgkin 2Carcinoma 2Adenocarcinoma of Lung 2Adenocarcinoma 2Thoracic Neoplasms 1Stomach Neoplasms 1Sarcoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Nonhematologic Malignancies 1Non-Squamous Non-Small Cell Lung Cancer 1Non - Small Cell Lung Cancer NSCLC 1Neuroendocrine Tumors 1NSCLC 1Metatropic dwarfism 1Metastatic HER2-positive Breast Cancer 1Lung Diseases 1Lethal Congenital Contracture Syndrome 2 1HR+HER2- Breast Cancer 1HER2-positive Advanced Breast Cancer 1Desmoplastic Small Round Cell Tumor 1

Interventions

pembrolizumab 44Carboplatin 28Cisplatin 26Paclitaxel 24Bevacizumab 21human papillomavirus vaccine, L1 type 16, 18 16Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 14atezolizumab 11Papillomavirus Vaccines 11Nivolumab 10tisotumab vedotin 8Vaccines, Synthetic 8Gemcitabine 8Colposcopy 8Topotecan 7fludarabine 6Vaccines 6Injections 6Cyclophosphamide 6spartalizumab 5balstilimab 5Pemetrexed 5Irinotecan 5Fulvestrant 5Docetaxel 5zimberelimab 4durvalumab 4Vinorelbine 4Ipilimumab 4Interleukin-2 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Uterine Cervical Neoplasms × Vinorelbine × Clear all
NCT06459180 2026-05-27

TroFuse-020

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
686 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT04697628 2026-02-24

innovaTV 301

Seagen Inc.

Phase 3 Completed
502 enrolled 18 charts 1 FDA
Gynecologic

Uterine Cervical Neoplasms

NCT03386721 2023-02-21

Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors

Hoffmann-La Roche

Phase 2 Terminated
256 enrolled 26 charts
Gynecologic

Uterine Cervical Neoplasms

NCT04943627 2022-10-05

Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)

Agenus Inc.

Phase 3 Withdrawn
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡